Global Multiple Sclerosis Drugs Market 2019-2023

Industry Insights

The global multiple sclerosis drugs market size will grow by USD 7.79 billion during 2019-2023 at a CAGR of close to 6%. The rising prevalence of multiple sclerosis and the development of novel drugs are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by type (oral and parenteral) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including Bayer AG, Biogen, Merck KGaA, Novartis AG, and Sanofi.

Key Insights from Multiple Sclerosis Drugs Market – Global Forecast 2019-2023

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the multiple sclerosis drugs market report

Request a FREE sample now!

The rising prevalence of multiple sclerosis is one of the key factors expected to trigger multiple sclerosis drugs market growth in the coming years. Several factors including genetic and environmental are contributing to the rising incidence of multiple sclerosis. Prevalence of autoimmune diseases, including type 1 diabetes and certain infections, including the infectious mononucleosis also lead to a surging risk of multiple sclerosis. With the rising incidence of this health condition, the demand for MS drugs will increase significantly in the coming years which will contribute to the growth of multiple sclerosis drugs market size.

The development of novel drugs is one of the key trends expected to gain traction in the market. Researchers have already discovered drugs that slow the progression of the symptoms of secondary progressive multiple sclerosis. Furthermore, the market has also witnessed increased approvals of innovative therapies for the treatment of relapsing forms of multiple sclerosis and primary-progressive multiple sclerosis. The rising development of novel drugs coupled with the growing prevalence of the disease will drive the multiple sclerosis drugs market growth at a CAGR of close to 6% during the forecast period.

Industry Analysis

Type Insights

The type segment has been segregated into oral and parenteral. The parenteral segment accounted for the highest multiple sclerosis drugs market share in 2018. However, the oral type segment will gain traction and account for the largest share by the end of the forecast period. During the forecast period, the oral segment will grow at a faster pace than the overall market. The parenteral segment will grow at a slower pace than the overall market.

The increasing prevalence of multiple sclerosis and the availability of oral disease-modifying drugs are some of the factors contributing to the growth of the multiple sclerosis drugs market in the oral type segment. 

Regional Insights

North America accounted for the highest market share in 2018. Though the market’s growth in this region will be slower than the growth of the market in Asia, the region will account for the largest multiple sclerosis drugs market share throughout the forecast period. The US is a key market for multiple sclerosis drugs in this region.

The presence of major vendors and increasing awareness initiatives and patient support will fuel multiple sclerosis drugs market growth in North America.

Top Multiple Sclerosis Drugs Manufacturers

The multiple sclerosis drugs market is moderately concentrated, and companies are launching innovative drugs for the treatment of this health condition. To help clients improve their position, this multiple sclerosis drugs market analysis report provides information on the competitive landscape and the products offered by various companies. Moreover, this multiple sclerosis drugs market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.

The report offers a detailed analysis of several leading multiple sclerosis drugs manufacturers, including:

• Bayer AG
• Biogen
• Merck KGaA
• Novartis AG
• Sanofi

Segments Covered in the Report

Multiple sclerosis drugs market by type

• Oral
• Parenteral

Multiple sclerosis drugs market by region

• Asia
• Europe
• North America
• ROW

Key Highlights of the Multiple Sclerosis Drugs Market Forecast Report for the Period 2019-2023 

• CAGR of the market during the forecast period 2019-2023 
• Detailed information on factors that will accelerate the growth of the multiple sclerosis drugs market size during the next five years 
• Precise estimation of the global multiple sclerosis drugs market size and its contribution to the parent market 
• Accurate predictions on upcoming trends and changes in consumer behavior 
• The growth of the multiple sclerosis drugs industry across Asia, Europe, North America, and ROW 
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors 
• Comprehensive details of factors that will challenge the growth of multiple sclerosis drugs companies

We can help! Our analysts can customize the market research report to meet your requirements. Get in touch